Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Toxoplasmosis in the compromised host

J Ruskin, J S Remington

    Annals of Internal Medicine
    |February 1, 1976
    PubMed
    Summary
    This summary is machine-generated.

    Toxoplasmosis in immunocompromised patients often presents with varied symptoms, predominantly neurological. Early diagnosis and treatment with chemotherapy significantly improve outcomes, suggesting immunotherapy as a future adjunct.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Inflammation, periodontitis, and coronary heart disease.

    Lancet (London, England)·2001
    Same author

    Long-term infection rates associated with the pectoral versus abdominal approach to cardioverter- defibrillator implants.

    The American journal of cardiology·2001
    Same author

    Diagnostic quiz #38. Case no. 1. Central giant cell granuloma.

    Today's FDA : official monthly journal of the Florida Dental Association·2001
    Same author

    Detection of immunoglobulin M antibodies to P35 antigen of Toxoplasma gondii for serodiagnosis of recently acquired infection in pregnant women.

    Journal of clinical microbiology·2000
    Same author

    Protection against lipopolysaccharide-induced death by fluoroquinolones.

    Antimicrobial agents and chemotherapy·2000
    Same author

    Strategies for the successful treatment of gram-positive bacterial infections.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2000
    Same journal

    Correction to I.M. Matters News: Sleep medicine for seniors.

    Annals of internal medicine·2026
    Same journal

    Adverse Events After Same-Day COVID-19 and Influenza Vaccination Versus Influenza Vaccination Alone : A Target Trial Emulation.

    Annals of internal medicine·2026
    Same journal

    Leveraging Real-World Evidence to Inform Regulatory, Clinical, and Coverage Decisions Related to Glucagon-Like Peptide-1-Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.

    Annals of internal medicine·2026
    Same journal

    Methodological Approaches to Real-World Evidence Generation for Glucagon-like Peptide-1-Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.

    Annals of internal medicine·2026
    Same journal

    Weekly and Biweekly Treatment With Bofanglutide Versus Semaglutide in Chinese Patients With Type 2 Diabetes : A Phase 2b Randomized Clinical Trial.

    Annals of internal medicine·2026
    Same journal

    Grappling with GLP-1 prescribing.

    Annals of internal medicine·2026
    See all related articles

    Area of Science:

    • Medical Parasitology
    • Immunology
    • Neurology

    Background:

    • Toxoplasmosis is a significant opportunistic infection in immunocompromised individuals, including those with neoplasia, collagen-vascular disorders, and organ allografts.
    • Clinical manifestations are diverse, with a predilection for neurological syndromes such as encephalopathy, meningoencephalitis, and cerebral mass lesions.
    • Concomitant infections, particularly with DNA viruses, are frequently observed in these patients.

    Purpose of the Study:

    • To analyze the clinical spectrum and diagnostic challenges of toxoplasmosis in immunocompromised patients.
    • To evaluate the efficacy of antitoxoplasma chemotherapy in this patient population.
    • To explore the role of cellular immunity and potential immunotherapeutic strategies for toxoplasmosis.

    Main Methods:

    Related Experiment Videos

    • Retrospective analysis of 81 cases of toxoplasmosis in patients with specific underlying conditions.
    • Review of clinical manifestations, diagnostic methods employed (biopsy, serology), and postmortem findings.
    • Assessment of treatment outcomes for patients receiving pyrimethamine and sulfonamide chemotherapy.

    Main Results:

    • Neurologic syndromes were the predominant clinical presentation.
    • Diagnosis was frequently delayed, often confirmed only postmortem.
    • Antitoxoplasma chemotherapy (pyrimethamine and sulfonamide) resulted in marked clinical improvement or remission in 80% of treated patients.

    Conclusions:

    • Disseminated toxoplasmosis in immunosuppressed hosts likely arises from impaired cellular immunity, leading to reactivation of latent infections.
    • Prompt diagnosis and chemotherapy are crucial for managing toxoplasmosis in immunocompromised patients.
    • Immunotherapy, by enhancing cell-mediated immunity, holds promise as an adjunct to chemotherapy for severe cases.